Pfizer has received early U.S. antitrust clearance more than a week early for its proposed $7.3 billion Metsera acquisition, which has been called into question by Novo Nordisk's higher $8.5 billion offer.

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the highly lucrative weight-loss drug market.

Pfizer has filed a lawsuit against Metsera and Novo Nordisk, claiming Metsera violated its merger agreement by entertaining Novo's superior bid offer. Pfizer seeks a court order to prevent Metsera from terminating their agreement,

U.S. drugmaker Pfizer could work its connections within President Donald Trump's administration to try to thwart Novo Nordisk's surprise rival bid to acquire U.S. obesity biotech firm Metsera, analysts,

Vertex should earn other important approvals through 2030 that could jolt its stock price. It's developing a treatment called zimislecel for type 1 diabetes (T1D), and the therapy is showing the ability to restore patients' insulin production in clinical trials.

Pfizer PFE will report its third-quarter 2025 earnings on Nov. 4, before market open. The Zacks Consensus Estimate for sales and earnings for the third quarter is pegged at $16.6 billion and 66 cents per share,

Pfizer said on Friday it has received an early clearance from the U.S. Federal Trade Commission for its proposed acquisition of Metsera , removing a key regulatory hurdle for the deal valued at up to $7.

One struggling pharma stock that could use a boost from a strong earnings report is Pfizer (NYSE: PFE). The company's valuation has plummeted in recent years as patent cliffs and